1
|
Beneduce C, Nguyen S, Washburn N, Schaeck J, Meccariello R, Holte K, Ortiz D, Manning AM, Bosques CJ, Kurtagic E. Inhibitory Fc-Gamma IIb Receptor Signaling Induced by Multivalent IgG-Fc Is Dependent on Sialylation. Cells 2023; 12:2130. [PMID: 37681862 PMCID: PMC10486564 DOI: 10.3390/cells12172130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/05/2023] [Accepted: 08/18/2023] [Indexed: 09/09/2023] Open
Abstract
Immunoglobulin (IgG) Fc glycosylation has been shown to be important for the biological activity of antibodies. Fc sialylation is important for the anti-inflammatory activity of IgGs. However, evaluating the structure-activity relationship (SAR) of antibody Fc glycosylation has been hindered using simplified in vitro models in which antibodies are often displayed in monomeric forms. Presenting antibodies in monomeric forms may not accurately replicate the natural environment of the antibodies when binding their antigen in vivo. To address these limitations, we used different Fc-containing molecules, displaying their Fc domains in monovalent and multivalent fashion. Given the inhibitory role of Fc gamma receptor IIb (FcγRIIb) in autoimmune and inflammatory diseases, we focused on evaluating the impact of Fc sialylation on the activation of FcγRIIb. We report for the first time that in human cellular systems, sialic acid mediates the induction of FcγRIIb phosphorylation by IgG-Fc when the IgG-Fc is displayed in a multivalent fashion. This effect was observed with different types of therapeutic agents such as sialylated anti-TNFα antibodies, sialylated IVIg and sialylated recombinant multivalent Fc products. These studies represent the first report of the specific effects of Fc sialylation on FcγRIIb signaling on human immune cells and may help in the characterization of the anti-inflammatory activity of Fc-containing therapeutic candidates.
Collapse
Affiliation(s)
- Christopher Beneduce
- Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA
- Janssen Research & Development, Cambridge, MA 02142, USA
| | | | - Nathaniel Washburn
- Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA
- Janssen Research & Development, Cambridge, MA 02142, USA
| | - John Schaeck
- Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA
| | - Robin Meccariello
- Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA
- Janssen Research & Development, Cambridge, MA 02142, USA
| | | | - Daniel Ortiz
- Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA
| | | | | | - Elma Kurtagic
- Momenta Pharmaceuticals Inc., Cambridge, MA 02142, USA
- Janssen Research & Development, Cambridge, MA 02142, USA
| |
Collapse
|
2
|
Washburn N, Meccariello R, Duffner J, Getchell K, Holte K, Prod'homme T, Srinivasan K, Prenovitz R, Lansing J, Capila I, Kaundinya G, Manning AM, Bosques CJ. Characterization of Endogenous Human FcγRIII by Mass Spectrometry Reveals Site, Allele and Sequence Specific Glycosylation. Mol Cell Proteomics 2020; 18:534-545. [PMID: 30559323 PMCID: PMC6398215 DOI: 10.1074/mcp.ra118.001142] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Revised: 11/21/2018] [Indexed: 12/21/2022] Open
Abstract
Characterization of endogenous FcγRIII glycosylation from healthy donors with different FcγRIIIb genotypes reveals site specific, and allele specific differences in glycosylation as well as noncananonical sequence specific differences in glycosylation. We propose these differences in glycosylation may influence the differential activity seen for neutrophils across genotypes. The importance of IgG glycosylation, Fc-gamma receptor (FcγR) single nucleotide polymorphisms and FcγR copy number variations in fine tuning the immune response has been well established. There is a growing appreciation of the importance of glycosylation of FcγRs in modulating the FcγR-IgG interaction based on the association between the glycosylation of recombinant FcγRs and the kinetics and affinity of the FcγR-IgG interaction. Although glycosylation of recombinant FcγRs has been recently characterized, limited knowledge exists on the glycosylation of endogenous human FcγRs. In order to improve the structural understanding of FcγRs expressed on human cells we characterized the site specific glycosylation of native human FcγRIII from neutrophils of 50 healthy donors and from matched plasma for 43 of these individuals. Through this analysis we have confirmed site specific glycosylation patterns previously reported for soluble FcγRIII from a single donor, identified FcγRIIIb specific Asn45 glycosylation and an allelic effect on glycosylation at Asn162 of FcγRIIIb. Identification of FcγRIIIb specific glycosylation allows for assignment of FcγRIIIb alleles and relative copy number of the two alleles where DNA/RNA is not available. Intriguingly the types of structures found to be elevated at Asn162 in the NA2 allele have been shown to destabilize the Fc:FcγRIII interaction resulting in a faster dissociation rate. These differences in glycosylation may in part explain the differential activity reported for the two alleles which have similar in vitro affinity for IgG.
Collapse
Affiliation(s)
- Nathaniel Washburn
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142.
| | - Robin Meccariello
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Jay Duffner
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Kristen Getchell
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Kimberly Holte
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Thomas Prod'homme
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Karunya Srinivasan
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Robert Prenovitz
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Jonathan Lansing
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Ishan Capila
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Ganesh Kaundinya
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Anthony M Manning
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| | - Carlos J Bosques
- From the ‡Research Department, Momenta Pharmaceuticals, 301 Binney St., Cambridge, Massachusetts 02142
| |
Collapse
|
3
|
Shade KTC, Conroy ME, Washburn N, Kitaoka M, Huynh DJ, Laprise E, Patil SU, Shreffler WG, Anthony RM. Sialylation of immunoglobulin E is a determinant of allergic pathogenicity. Nature 2020; 582:265-270. [PMID: 32499653 PMCID: PMC7386252 DOI: 10.1038/s41586-020-2311-z] [Citation(s) in RCA: 80] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Accepted: 03/11/2020] [Indexed: 01/28/2023]
Abstract
Approximately one-third of the world's population suffers from allergies1. Exposure to allergens crosslinks immunoglobulin E (IgE) antibodies that are bound to mast cells and basophils, triggering the release of inflammatory mediators, including histamine2. Although IgE is absolutely required for allergies, it is not understood why total and allergen-specific IgE concentrations do not reproducibly correlate with allergic disease3-5. It is well-established that glycosylation of IgG dictates its effector function and has disease-specific patterns. However, whether IgE glycans differ in disease states or affect biological activity is completely unknown6. Here we perform an unbiased examination of glycosylation patterns of total IgE from individuals with a peanut allergy and from non-atopic individuals without allergies. Our analysis reveals an increase in sialic acid content on total IgE from individuals with a peanut allergy compared with non-atopic individuals. Removal of sialic acid from IgE attenuates effector-cell degranulation and anaphylaxis in several functional models of allergic disease. Therapeutic interventions-including removing sialic acid from cell-bound IgE with a neuraminidase enzyme targeted towards the IgE receptor FcεRI, and administering asialylated IgE-markedly reduce anaphylaxis. Together, these results establish IgE glycosylation, and specifically sialylation, as an important regulator of allergic disease.
Collapse
Affiliation(s)
- Kai-Ting C Shade
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Michelle E Conroy
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Maya Kitaoka
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Daniel J Huynh
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Emma Laprise
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Sarita U Patil
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Division of Pediatric Allergy and the MGH Food Allergy Center, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Food Allergy Science Initiative at the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA
| | - Wayne G Shreffler
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Division of Pediatric Allergy and the MGH Food Allergy Center, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.,Food Allergy Science Initiative at the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA
| | - Robert M Anthony
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
4
|
Rutitzky L, Ortiz DF, Lansing JC, Brown J, Paquette J, Garofalo K, D'Alessandro J, Bhatnagar N, Hains M, Gupta A, Lee S, Zouaoui R, Wang J, Schaeck J, Marchese S, Meccariello R, Washburn N, Holte K, Bosques CJ, Manning AM. Abstract 3244: Improved Fc-mediated effector functions by an anti-CTLA-4 multivalent Fc agent. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Numerous therapeutic monoclonal antibodies (mAbs) rely on antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC) Fc effector functions to deplete target cells and achieve clinical efficacy. It has been previously shown that adding multiple Fc domains to Abs or afucosylating the Fc domain increases Fc effector functions. We have leveraged a proprietary Fc multimerization technology (SIF; selective immunomodulator of Fc receptors) to identify potential novel products designed to improve the immune system’s elimination of tumor and other pathogenic cells. These agents utilize the valency effect of Fc multimerization to increase the binding to Fc receptors and complement, enhancing immune-mediated cytotoxicity mechanisms. CTLA-4 is a clinically validated immune checkpoint inhibitor exemplified by the human IgG1 therapeutic mAb ipilimumab. CTLA-4 is induced upon activation on T cells and constitutively expressed on T regulatory cells (Tregs). Based on data from mouse models of cancer and clinical studies, the proposed mechanisms of action of anti-CTLA-4 mAbs, including ipilimumab, are to block the interaction of CTLA-4 with its ligands CD80 and CD86 resulting in T cell activation and to induce Fc-mediated ADCC of CTLA-4+ cells, mainly intratumoral Tregs. Therefore, we have produced an anti-CTLA-4 multivalent IgG1 Fc agent termed anti-CTLA-4 SIFbody with the purpose of enhancing binding to Fc gamma receptors (FcγRs) and complement and increasing Fc-mediated elimination of intratumoral Tregs. Data from avidity binding to low affinity FcγRs showed more than 100-fold increase with anti-CTLA-4 SIFbody as compared to ipilimumab. In in vitro functional assays using CTLA-4 transfected target cells and primary human effector cells, anti-CTLA-4 SIFbody showed more than 10-fold increase in potency in ADCC and more than 5-fold increase in ADCP as compared to ipilimumab. Anti-CTLA-4 SIFbody induced 80% cell lysis by CDC, whereas ipilimumab failed to show any activity. More importantly, we generated in vitro expanded Tregs with suppressive function and showed that anti-CTLA-4 SIFbody induced significant enhanced ADCC on these cells as compared to ipilimumab and to an afucosylated anti-CTLA-4 mAb. ADCP was also significantly increased on Tregs. Unexpectedly, Tregs were resistant to anti-CTLA-4 SIFbody induced CDC. Notably, the blocking activity of the SIFbody F(ab)s was not altered by the multivalent Fc structure as shown by similar CTLA-4/CD80 and CD86 blockade and induction of IL-2 production upon antigen stimulation of PBMC. In conclusion, these data demonstrate that our Fc multimerization technology applied to an anti-CTLA-4 mAb significantly improves Fc-dependent immune-mediated cytotoxicity and suggest that anti-CTLA-4 SIFbody may represent an optimized novel product to deplete intratumoral Tregs and enhance anti-tumor activity.
Citation Format: Laura Rutitzky, Daniel F. Ortiz, Jonathan C. Lansing, Julia Brown, Joseph Paquette, Kevin Garofalo, Josephine D'Alessandro, Naveen Bhatnagar, Maurice Hains, Abhinav Gupta, Stan Lee, Radouane Zouaoui, Jason Wang, John Schaeck, Salvatore Marchese, Robin Meccariello, Nathaniel Washburn, Kimberly Holte, Carlos J. Bosques, Anthony M. Manning. Improved Fc-mediated effector functions by an anti-CTLA-4 multivalent Fc agent [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3244.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Stan Lee
- Momenta Phamaceuticals Inc, Cambridge, MA
| | | | - Jason Wang
- Momenta Phamaceuticals Inc, Cambridge, MA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, Washburn N, Bhatnagar N, Beneduce C, Holte K, Prenovitz R, Child M, Killough J, Tyler S, Brown J, Nguyen S, Schwab I, Hains M, Meccariello R, Markowitz L, Wang J, Zouaoui R, Simpson A, Schultes B, Capila I, Ling L, Nimmerjahn F, Manning AM, Bosques CJ. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. Sci Transl Med 2017; 8:365ra158. [PMID: 27856797 DOI: 10.1126/scitranslmed.aaf9418] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Accepted: 09/29/2016] [Indexed: 12/18/2022]
Abstract
Autoantibody immune complex (IC) activation of Fcγ receptors (FcγRs) is a common pathogenic hallmark of multiple autoimmune diseases. Given that the IC structural features that elicit FcγR activation are poorly understood and the FcγR system is highly complex, few therapeutics can directly block these processes without inadvertently activating the FcγR system. To address these issues, the structure activity relationships of an engineered panel of multivalent Fc constructs were evaluated using sensitive FcγR binding and signaling cellular assays. These studies identified an Fc valency with avid binding to FcγRs but without activation of immune cell effector functions. These observations directed the design of a potent trivalent immunoglobulin G-Fc molecule that broadly inhibited IC-driven processes in a variety of immune cells expressing FcγRs. The Fc trimer, Fc3Y, was highly efficacious in three different animal models of autoimmune diseases. This recombinant molecule may represent an effective therapeutic candidate for FcγR-mediated autoimmune diseases.
Collapse
Affiliation(s)
- Daniel F Ortiz
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Jonathan C Lansing
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Laura Rutitzky
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Elma Kurtagic
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Thomas Prod'homme
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Amit Choudhury
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Nathaniel Washburn
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Naveen Bhatnagar
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | | | - Kimberly Holte
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Robert Prenovitz
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Matthew Child
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Jason Killough
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Steven Tyler
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Julia Brown
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Stephanie Nguyen
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Inessa Schwab
- Department of Biology, Institute of Genetics, University of Erlangen-Nürnberg, 91058 Erlangen, Germany
| | - Maurice Hains
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Robin Meccariello
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Lynn Markowitz
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Jing Wang
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Radouane Zouaoui
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Allison Simpson
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Birgit Schultes
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Ishan Capila
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Leona Ling
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Falk Nimmerjahn
- Department of Biology, Institute of Genetics, University of Erlangen-Nürnberg, 91058 Erlangen, Germany
| | - Anthony M Manning
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA
| | - Carlos J Bosques
- Momenta Pharmaceuticals, 675 West Kendall Street, Cambridge, MA 02142, USA.
| |
Collapse
|
6
|
Washburn N, Meccariello R, Hu S, Hains M, Bhatnagar N, Sarvaiya H, Kapoor B, Schaeck J, Pino I, Manning A, Lansing JC, Bosques CJ. High-resolution physicochemical characterization of different intravenous immunoglobulin products. PLoS One 2017; 12:e0181251. [PMID: 28759653 PMCID: PMC5536303 DOI: 10.1371/journal.pone.0181251] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 06/28/2017] [Indexed: 01/12/2023] Open
Abstract
Intravenous immunoglobulin (IVIg) is a complex mixture drug comprising diverse immunoglobulins and non-IgG proteins purified from the plasma of thousands of healthy donors. Approved IVIg products on the market differ regarding source of plasma, isolation process, and formulation. These products are used widely, and often interchangeably, for the treatment of immunodeficiency and autoimmune and inflammatory diseases, but their mechanisms of action in different indications are not well understood. A primary limitation to understanding the therapeutic relevance of specific components within IVIg has been the limited resolution of analytics historically implemented to characterize its complex mixture. In this study, high-resolution analytics were applied to better understand the composition of IVIg and product variations. We characterized three approved IVIg products: Gammagard®, Privigen®, and Octagam®. Differences in the distribution of molecular weight species, IgG sequence variants, isoforms, glycoforms, and the repertoire of previously reported antibody specificities were identified. We also compared the effect of aging on these products to identify changes in size distribution and posttranslational modifications. This type of characterization may provide insights into the specific factors and components of IVIg that may influence its activity and ultimately lead to optimization of IVIg products for use in autoimmune diseases.
Collapse
Affiliation(s)
- Nathaniel Washburn
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Robin Meccariello
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Shaohui Hu
- Research, CDI Laboratories, Baltimore, Maryland, United States of America
| | - Maurice Hains
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Naveen Bhatnagar
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Hetal Sarvaiya
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Bulbul Kapoor
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - John Schaeck
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Ignacio Pino
- Research, CDI Laboratories, Mayaguez, Puerto Rico
| | - Anthony Manning
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Jonathan C. Lansing
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
| | - Carlos J. Bosques
- Research, Momenta Pharmaceuticals, Cambridge, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|
7
|
Bosques C, Lansing J, Ortiz D, Rutitzky L, Washburn N, Bhatnagar N, Kurtagic E, Choudhury A, Prod'homme T, Schultes B, Roy S, Kaundinya G, Manning A. AB0443 Selective Immunomodulators of FC-Gamma Receptors (SIFS) to Inhibit Autoantibody-Mediated Pathology. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
8
|
Srinivasan K, Roy S, Washburn N, Sipsey SF, Meccariello R, Meador JW, Ling LE, Manning AM, Kaundinya GV. A Quantitative Microtiter Assay for Sialylated Glycoform Analyses Using Lectin Complexes. ACTA ACUST UNITED AC 2015; 20:768-78. [PMID: 25851037 PMCID: PMC4512520 DOI: 10.1177/1087057115577597] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2014] [Accepted: 02/22/2015] [Indexed: 12/12/2022]
Abstract
Fidelity of glycan structures is a key requirement for biotherapeutics, with carbohydrates playing an important role for therapeutic efficacy. Comprehensive glycan profiling techniques such as liquid chromatography (LC) and mass spectrometry (MS), while providing detailed description of glycan structures, require glycan cleavage, labeling, and paradigms to deconvolute the considerable data sets they generate. On the other hand, lectins as probes on microarrays have recently been used in orthogonal approaches for in situ glycoprofiling but require analyte labeling to take advantage of the capabilities of automated microarray readers and data analysis they afford. Herein, we describe a lectin-based microtiter assay (lectin–enzyme-linked immunosorbent assay [ELISA]) to quantify terminal glycan moieties, applicable to in vitro and in-cell glycan-engineered Fc proteins as well as intact IgGs from intravenous immunoglobulin (IVIG), a blood product containing pooled polyvalent IgG antibodies extracted from plasma from healthy human donors. We corroborate our findings with industry-standard LC-MS profiling. This “customizable” ELISA juxtaposes readouts from multiple lectins, focusing on a subset of glycoforms, and provides the ability to discern single- versus dual-arm glycosylation while defining levels of epitopes at sensitivities comparable to MS. Extendable to other biologics, this ELISA can be used stand-alone or complementary to MS for quantitative glycan analysis.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Leona E Ling
- Momenta Pharmaceuticals, Inc., Cambridge, MA, USA
| | | | | |
Collapse
|
9
|
Shade KTC, Platzer B, Washburn N, Mani V, Bartsch YC, Conroy M, Pagan JD, Bosques C, Mempel TR, Fiebiger E, Anthony RM. A single glycan on IgE is indispensable for initiation of anaphylaxis. ACTA ACUST UNITED AC 2015; 212:457-67. [PMID: 25824821 PMCID: PMC4387292 DOI: 10.1084/jem.20142182] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Accepted: 03/11/2015] [Indexed: 12/02/2022]
Abstract
Shade et al. demonstrate the requirement for IgE glycosylation in allergic reactions. Immunoglobulin ε (IgE) antibodies are the primary mediators of allergic diseases, which affect more than 1 in 10 individuals worldwide. IgE specific for innocuous environmental antigens, or allergens, binds and sensitizes tissue-resident mast cells expressing the high-affinity IgE receptor, FcεRI. Subsequent allergen exposure cross-links mast cell–bound IgE, resulting in the release of inflammatory mediators and initiation of the allergic cascade. It is well established that precise glycosylation patterns exert profound effects on the biological activity of IgG. However, the contribution of glycosylation to IgE biology is less clear. Here, we demonstrate an absolute requirement for IgE glycosylation in allergic reactions. The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse. Genetic disruption of the site or enzymatic removal of the oligomannose glycan altered IgE secondary structure and abrogated IgE binding to FcεRI, rendering IgE incapable of eliciting mast cell degranulation, thereby preventing anaphylaxis. These results underscore an unappreciated and essential requirement of glycosylation in IgE biology.
Collapse
Affiliation(s)
- Kai-Ting C Shade
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| | - Barbara Platzer
- Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115 Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115
| | | | - Vinidhra Mani
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| | - Yannic C Bartsch
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| | - Michelle Conroy
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| | - Jose D Pagan
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| | | | - Thorsten R Mempel
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| | - Edda Fiebiger
- Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115 Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115
| | - Robert M Anthony
- Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129
| |
Collapse
|
10
|
Adkins BW, Titus-Howard T, Massey V, Washburn N, Molinaro J, Lang B, Bruning WL, Lanoue K. A collaborative demonstration project: Depression screening in patient with cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18556 Background: A demonstration project testing the feasibly of implementing a depression screening work flow algorithm was initiated by the anti-depression committee at one of six ambulatory care sites in the Kansas City Cancer Center (KCCC) system. The object of the study was to develop a process of work flow that would assist in identifying patients with depression and facilitate appropriate interventions by providers. Methods: A flow chart was developed illustrating critical decision-making points in the screening for depression by physicians and nurse practitioners (NP). The population included half radiation therapy and the other half chemotherapy. Patients completed the PHQ-2 a two question prescreen to assess initial symptoms of depression, including feeling depressed, down or hopeless and/ or little interest or pleasure in activities. A positive response to one of these 2 questions prompted the administration of the PHQ-9 a validated depression screening instrument. The PHQ-9 scoring criteria was used to assist the physician and NP with taking the appropriate action such as the initiation of antidepressant therapy and/or referral to mental health provider, follow up for subsequent appointments and/or reassessment. Results: Seventy-one patients were tracked to evaluate the process of recognition and management of depression from April 2004 to January 2005. Of the 71 patients 37% (N = 26) scored positive on at least one question on the two question prescreen. Of the 26 patients scoring positive 27% (N = 7) of these patients had less than 3 follow up visits while 73 % (N = 19) had greater than 3 follow-up visits by the KCCC providers. Of the patients that answered positively to one of the two prescreen questions 69% (N = 18) completed the full PHQ-9 and their scores were recorded. Conclusions: The development of a new model in a community-based oncology practice allows for integrating clinically proven techniques for diagnosing and treating depression. It will allow for the committee to make recommendations for changes in the process before it is implemented on a larger scale at all KCCC outpatient sites. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. W. Adkins
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - T. Titus-Howard
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - V. Massey
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - N. Washburn
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - J. Molinaro
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - B. Lang
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - W. L. Bruning
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| | - K. Lanoue
- Kansas City Cancer Center, Overland Park, KS; Mid-America Coalition on Health Care, Kansas City, MO; Kansas City Cancer Center, Kansas City, MO
| |
Collapse
|
11
|
Adkins BW, Washburn N, Simmons S, Gerken P, Sommer V, Rogers B, LaNoue K, Wilson B. Recognizing depression in outpatient oncology patient population: A quality improvement project. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. W. Adkins
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - N. Washburn
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - S. Simmons
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - P. Gerken
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - V. Sommer
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - B. Rogers
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - K. LaNoue
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| | - B. Wilson
- Kansas City Cancer Ctr, Overland Prk, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Kansas City, MO; Kansas City Cancer Ctr, Lee’s Summit, MO
| |
Collapse
|
12
|
Ethirajan S, Adkins B, Spencer S, Gerken P, Washburn N, Simmons S, Sommer V, Rogers M, Strauss Tranin A. Genetic risk assessment in women with breast cancer in the outpatient setting: Establishing the standard of practice for ambulatory care clinics. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Ethirajan
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - B. Adkins
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - S. Spencer
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - P. Gerken
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - N. Washburn
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - S. Simmons
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - V. Sommer
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - M. Rogers
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| | - A. Strauss Tranin
- Kansas City Cancer Centers, Overland Park, KS; Kansas City Cancer Centers, Kansas City, MO; Kansas City Cancer Centers, Kansas City, KS; Kansas City Cancer Centers, Lee's Summit, MO; Cancer Genetic Counseling, Overland Park, KS
| |
Collapse
|
13
|
Dunkers J, Cicerone M, Washburn N. Collinear optical coherence and confocal fluorescence microscopies for tissue engineering. Opt Express 2003; 11:3074-3079. [PMID: 19471428 DOI: 10.1364/oe.11.003074] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Tissue engineered medical products (TEMPs) are often three-dimensional (3D) hybrid materials consisting of a porous scaffold upon which the tissue is grown. However, monitoring of the developing tissue deep within the scaffold is hampered by its turbidity. We have sought new ways to probe the interior of the scaffold with the same resolution as conventional laser scanning confocal microscopy but with greater sensitivity. We present a novel application of optical coherence microscopy (OCM) by combining it with confocal fluorescence microscopy (CFM) togather simultaneous structural and functional information on TEMPs in a registered fashion. In this work, we describe the collinear OCM and CFM instrument. We demonstrate the utility of this dual-mode technique for TEMPs by imaging fluorescently stained osteoblasts cultured in a polymeric TEMP.
Collapse
|